| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -7.0 | -5.7 |
| EPS (diluted, $ a share) | $-1.76 | $-1.50 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: TVGN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Tevogen Inc.: key numbers
- Share price
- $6.22Close, Nov 16
- Market cap
- $40.5M
- Shares outstanding
- 6.51MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Tevogen Inc.
All →Tevogen Leadership Change
Susan Podlogar resigned from the Board of Directors of Tevogen Inc. effective November 2, 2026. Following the resignation, the Board reduced its size from six to five members and appointed current director Lindee Goh to the Audit Committee.
Tevogen $36M Debt Financing with The Patel Family, LLP
Tevogen Inc. amended its unsecured line of credit with The Patel Family, LLP, extending the borrowing period to May 31, 2029, and fixing the share price for debt repayment at $7.40 per share. Following the amendment, the company issued approximately 1.02 million shares to repay the entire $7.4 million outstanding principal balance and accrued interest, effectively eliminating its current debt liabilities.
- Value
- $36M
- Counterparty
- The Patel Family, LLP
- Term
- through May 2029
Tevogen Nasdaq/NYSE Compliance Notice
Tevogen Inc. received written notice from Nasdaq confirming it has regained compliance with the $50 million minimum market value of listed securities requirement under Nasdaq Listing Rule 5450(b)(2)(A). This follows a previous notice regarding the market value of publicly held shares, and with both requirements now satisfied, all related Nasdaq compliance matters are closed.
- Counterparty
- The Nasdaq Stock Market LLC
Tevogen Stock Plan Amendment
Tevogen Inc. granted performance-based restricted stock awards to its CEO Ryan Saadi (8,000,000 shares) and CFO Kirti Desai (750,000 shares) under the 2024 Omnibus Incentive Plan. Vesting is contingent upon the company achieving a $1.0 billion aggregate revenue threshold by September 30, 2031. The grants are intended to align executive compensation with long-term growth and stockholder value creation.
- Term
- through Sep 2031